Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $115.25

Illumina, Inc. (NASDAQ:ILMN) has earned an average recommendation of “Hold” from the nineteen brokerages that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $115.25.

Several research analysts recently weighed in on the stock. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research note on Tuesday, September 2nd. Evercore ISI cut their target price on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Robert W. Baird set a $105.00 target price on shares of Illumina in a research note on Friday. Daiwa Capital Markets downgraded shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a research note on Tuesday, August 12th. Finally, Scotiabank downgraded shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a research note on Friday, July 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. increased its stake in shares of Illumina by 0.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares during the last quarter. Bouvel Investment Partners LLC increased its stake in shares of Illumina by 2.3% during the 3rd quarter. Bouvel Investment Partners LLC now owns 6,129 shares of the life sciences company’s stock valued at $582,000 after acquiring an additional 136 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Illumina by 2.5% during the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after acquiring an additional 145 shares during the last quarter. Finally, Arkadios Wealth Advisors increased its stake in shares of Illumina by 1.7% during the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock valued at $871,000 after acquiring an additional 157 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.1%

NASDAQ:ILMN opened at $100.11 on Wednesday. The company has a market capitalization of $15.39 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.40. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a fifty day simple moving average of $98.17 and a 200-day simple moving average of $91.50.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $0.36 EPS. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.